This is a news story, published by Yahoo, that relates primarily to AstraZeneca news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
breast cancer drug. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest cheaper chemotherapy agent news, chemotherapy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
chemotherapy agentReuters
•83% Informative
AstraZeneca 's Truqap in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial.
Triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known actionable biomarker targets.
VR Score
93
Informative language
99
Neutral language
79
Article tone
formal
Language
English
Language complexity
77
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links